Novogen posts increased revenue
31 August, 2005 by Ruth BeranPharmaceutical company Novogen (ASX:NRT) saw revenues of AUD$17.7 million for 2004-05, a 7.5 per cent increase on the previous year, and a net loss of $11.1 million.
New research facilities open in WA, Qld
31 August, 2005 by Staff WritersTwo new research facilities have opened their doors, one a joint venture between the University of Western Australia (UWA) and the Western Australian Institute for Medical Research (WAIMR), and the other based at the University of Queensland's Institute for Molecular Bioscience (IMB).
ZingoTX nets $1.45m fed grant
30 August, 2005 by Helen SchullerPain management company ZingoTX, a subsidiary of Eqitx (ASX:EQX) has been awarded a AUD$1.45 million AusIndustry Commercial Ready grant to support the ZingoTX drug development program over the next 12 months.
Neuren initiates phase II trial
30 August, 2005 by Helen SchullerAuckland biopharma Neuren Pharmaceuticals (ASX: NEU) has begun to recruit the 30 patients who will take part in its phase II pharmacokinetics and safety trial of its lead drug Glypromate.
Metabolic records 'straightforward' result
29 August, 2005 by Helen SchullerMelbourne-based Metabolic Pharmaceuticals (ASX:MBP) has reported a loss of AUD$10.7 million for the year ended 30 June 2005, up 13 per cent from $9.5 million last year.
SciGen revenues, loss up
29 August, 2005 by Ruth BeranSingapore-based generics company SciGen (ASX:SIE) has posted a net loss of SGD$5.6 million (AUD$4.43 million) for 2004-05, up 29 per cent from the previous financial year.
Orchestrating serendipity
29 August, 2005 by Ann UldridgeAnn Uldridge explains the reasoning behind a new group for women in the biotechnology industry.
NeuroSolutions appoints Sigma Aldrich for scale-up
26 August, 2005 by Helen SchullerNeuroSolutions, the UK based subsidiary of newly listed neurology-focused biotech company NeuroDiscovery (ASX:NDL) has identified and selected Sigma Aldrich to provide scale-up and manufacturing services in relation to its lead pain drug candidate, NSL-043, which is due to enter a phase I clinical trial later this year.
Acrux posts steady revenue growth
25 August, 2005 by Ruth BeranMelbourne-based Acrux (ASX:ACR) posted revenue of AUD$4.8 million for the year ended June 30, 2005, up $1 million from the previous financial year, but also saw an increase in its net loss from $4.2 million in the previous year to $6 million in 2004-05.
Ambri revenue, loss down
25 August, 2005 by Ruth BeranAmbri (ASX:ABI) saw a decrease in its revenue for the 2004-05 financial year of 27 per cent to $1 million (from $1.4 million in the previous year) but the company's loss was also down 22 per cent to $9 million.
Peptech cheered by prostate cancer diagnostic trial
25 August, 2005 by Graeme O'NeillSydney peptide therapeutics company Peptech (ASX:PTD) has reported positive results from a trial of a prostate cancer diagnostic developed by its joint-venture partner Biosceptre International.
Benitec wins IP stoush
25 August, 2005 by Graeme O'NeillGene therapy company Benitec (ASX:BLT) has weathered a head-on challenge from US rival, Nucleonics, to its key DNA-directed RNA-interference (ddRNAi) patents.
In brief: Meditech, Psivida, Regenera, Mesoblast
24 August, 2005 by Staff WritersCancer biopharma Meditech Research (ASX:MTR) has been offered a AUD$2.98 million AusIndustry Commercial Ready Grant over the next three years towards the development and commercialisation of its lead anti-cancer product HyCAMP, which is in Phase II clinical testing.
Former AustCancer CEO to head US biotech
24 August, 2005 by Staff WritersPaul Hopper, who until earlier this year was at the helm of Australian company AustCancer (now Avantogen) has been named the CEO of New York-based clinical stage drug developer Evolve Oncology.
Another flat quarter, but PwC expects biotech recovery
24 August, 2005 by Iain ScottThe latest edition of PricewaterhouseCoopers' quarterly BioForum report is published today, and shows a second consecutive decline in Australian life science stocks in Q4 of the 2004-05 financial year.
